Increased superoxide production and altered nitric oxide-mediated relaxation in the aorta of young but not old male relaxin-deficient mice

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 309, Issue 2, 2015, Pages H285-H296

  Ng, Hooi H ^a   Jelinic, Maria ^a   Parry, Laura J ^a   Leo, Chen Huei ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Aorta; Endothelium; Nitric oxide; Relaxin; Superoxide

Indexed keywords

3 NITROTYROSINE; APOCYNIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; ENDOTHELIAL NITRIC OXIDE SYNTHASE; GLYCERYL TRINITRATE; INDOMETACIN; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE; PROSTACYCLIN; PROSTACYCLIN SYNTHASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 2; RELAXIN; SCAVENGER; SUPEROXIDE; TEMPOL; G PROTEIN COUPLED RECEPTOR; LGR7 PROTEIN, MOUSE; NOS3 PROTEIN, MOUSE; PROSTAGLANDIN SYNTHASE INHIBITOR; VASODILATOR AGENT;

ABDOMINAL AORTA; AGED; AGING; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; GENE EXPRESSION; GROUPS BY AGE; MALE; MOUSE; MYOGRAPHY; NONHUMAN; NUCLEOTIDE SEQUENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE; AGE; ANIMAL; AORTA; C57BL MOUSE; COMPARATIVE STUDY; DEFICIENCY; DOSE RESPONSE; DRUG EFFECTS; GENETICS; GENOTYPE; KNOCKOUT MOUSE; METABOLISM; SEX DIFFERENCE; SIGNAL TRANSDUCTION; VASODILATATION;

AGE FACTORS; ANIMALS; AORTA; CYCLOOXYGENASE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENOTYPE; MALE; MICE, INBRED C57BL; MICE, KNOCKOUT; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; PHENOTYPE; RECEPTORS, G-PROTEIN-COUPLED; RELAXIN; SEX FACTORS; SIGNAL TRANSDUCTION; SUPEROXIDES; VASODILATION; VASODILATOR AGENTS;

EID: 84937414775     PISSN: 03636135     EISSN: 15221539     Source Type: Journal    
DOI: 10.1152/ajpheart.00786.2014     Document Type: Article

References (24)

1. Bonner JS, Lantier L, Hocking KM, Kang L, Owolabi M, James FD, Bracy DP, Brophy CM, Wasserman DH. Relaxin treatment reverses insulin resistance in mice fed a high-fat diet. Diabetes 62: 3251-3260, 2013.
2. Collino M, Rogazzo M, Pini A, Benetti E, Rosa AC, Chiazza F, Fantozzi R, Bani D, Masini E. Acute treatment with relaxin protects the kidney against ischaemia/reperfusion injury. J Cell Mol Med 17: 1494-1505, 2013.
3. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471, 2011.
4. Dschietzig T, Bartsch C, Richter C, Laule M, Baumann G, Stangl K. Relaxin, a pregnancy hormone, is a functional endothelin-1 antagonist: attenuation of endothelin-1-mediated vasoconstriction by stimulation of endothelin type-B receptor expression via ERK-1/2 and nuclear factor-_B. Circ Res 92: 32-40, 2003.
5. Dschietzig T, Brecht A, Bartsch C, Baumann G, Stangl K, Alexiou K. Relaxin improves TNF-_-induced endothelial dysfunction: the role of glucocorticoid receptor and phosphatidylinositol 3-kinase signalling. Cardiovasc Res 95: 97-107, 2012.
6. Failli P, Nistri S, Quattrone S, Mazzetti L, Bigazzi M, Sacchi TB, DB. Relaxin up-regulates inducible nitric oxide synthase expression and nitric oxide generation in rat coronary endothelial cells. FASEB J 16: 252-254, 2002.
7. Gooi JH, Richardson ML, Jelinic M, Girling JE, Wlodek ME, Tare M, Parry LJ. Enhanced uterine artery stiffness in aged pregnant relaxin mutant mice is reversed with exogenous relaxin treatment. Biol Reprod 89: 18, 2013.
8. Herrera MD, Mingorance C, Rodríguez-Rodríguez R, Alvarez de Sotomayor M. Endothelial dysfunction and aging: an update. Ageing Res Rev 9: 142-152, 2010.
9. Jelinic M, Leo CH, Post Uiterweer ED, Sandow SL, Gooi JH, Wlodek ME, Conrad KP, Parkington H, Tare M, Parry LJ. Localization of relaxin receptors in arteries and veins, and region-specific increases in compliance and bradykinin-mediated relaxation after in vivo serelaxin treatment. FASEB J 28: 275-287, 2014.
10. Jeyabalan A, Novak J, Danielson LA, Kerchner LJ, Opett SL, Conrad KP. Essential role for vascular gelatinase activity in relaxin-induced renal vasodilation, hyperfiltration, and reduced myogenic reactivity of small arteries. Circ Res 93: 1249-1257, 2003.
11. Leo CH, Hart JL, Woodman OL. 3=,4=-dihydroxyflavonol reduces superoxide and improves nitric oxide function in diabetic rat mesenteric arteries. PLos One 6: e20813-e20823, 2011.
12. Leo CH, Hart JL, Woodman OL. Impairment of both nitric oxide-mediated and EDHF-type relaxation in small mesenteric arteries from rats with streptozotocin- induced diabetes. Br J Pharmacol 162: 365-377, 2011.
13. Leo CH, Jelinic M, Gooi JH, Tare M, Parry LJ. A vasoactive role for endogenous relaxin in mesenteric arteries of male mice. PLos One 9: e107382, 2014.
14. Leo CH, Jelinic M, Parkington HC, Tare M, Parry LJ. Acute intravenous injection of serelaxin (recombinant human relaxin-2) causes rapid and sustained bradykinin-mediated vasorelaxation. J Am Heart Assoc 3: e000493-e000508, 2014.
15. Masini E, Cuzzocrea S, Mazzon E, Muia C, Vannacci A, Fabrizi F, Bani D. Protective effects of relaxin in ischemia/reperfusion-induced intestinal injury due to splanchnic artery occlusion. Br J Pharmacol 148: 1124-1132, 2006.
16. McGuane JT, Debrah JE, Sautina L, Jarajapu YP, Novak J, Rubin JP, Grant MB, Segal M, Conrad KP. Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152: 2786-2796, 2011.
17. Novak J, Parry LJ, Matthews JE, Kerchner LJ, Indovina K, Hanley- Yanez K, Doty KD, Debrah DO, Shroff SG, Conrad KP. Evidence for local relaxin ligand-receptor expression and function in arteries. FASEB J 20: 2352-2362, 2006.
18. Novak J, Ramirez RJ, Gandley RE, Sherwood OD, Conrad KP. Myogenic reactivity is reduced in small renal arteries isolated from relaxin-treated rats. Am J Physiol Regul Integr Comp Physiol 283: R349-R355, 2002.
19. Sasser JM, Cunningham MWJ, Baylis C. Serelaxin reduces oxidative stress and asymmetric dimethylarginine in angiotensin II-induced hypertension. Am J Physiol Renal Physiol 307: F1355-F1362, 2014.
20. Soh YM, Tiwari A, Mahendroo M, Conrad KP, Parry LJ. Relaxin regulates hyaluranan synthesis and aquaporins in the cervix of late pregnant mice. Endocrinology 153: 6054-6064, 2012.
21. Toda N. Age-related changes in endothelial function and blood flow regualtion. Pharmacol Ther 133: 159-176, 2012.
22. van Drongelen J, Ploemen IH, Pertijs J, Gooi JH, Sweep FC, Lotgering FK, Spaanderman ME, Smits P. Aging attenuates the vasodilator response to relaxin. Am J Physiol Heart Circ Physiol 300: H1609-H1615, 2011.
23. van Drongelen J, van Koppen A, Pertijs J, Gooi JH, Parry LJ, Sweep FC, Lotgering FK, Smits P, Spaanderman ME. Impaired vascular responses to relaxin in diet-induced overweight female rats. J Appl Physiol 112: 962-969, 2012.
24. Vodstrcil LA, Tare M, Novak J, Dragomir N, Ramirez RJ, Wlodek ME, Conrad KP, Parry LJ. Relaxin mediates uterine artery compliance during pregnancy and increases uterine blood flow. FASEB J 26: 4035-4044, 2012